News
EXOZ
10.90
-2.02%
-0.22
Weekly Report: what happened at EXOZ last week (1222-1226)?
Weekly Report · 12/29/2025 09:24
Weekly Report: what happened at EXOZ last week (1215-1219)?
Weekly Report · 12/22/2025 09:24
Exozymes CEO Joins Beryl Elites Panel on AI in Life Sciences
Reuters · 12/15/2025 15:09
Weekly Report: what happened at EXOZ last week (1208-1212)?
Weekly Report · 12/15/2025 09:26
eXoZymes Achieves Major NCT Production Scale-Up
TipRanks · 12/12/2025 11:33
Exozymes Achieves 99% Conversion in Scaled Cell-Free Biomanufacturing
Reuters · 12/11/2025 21:10
Weekly Report: what happened at EXOZ last week (1201-1205)?
Weekly Report · 12/08/2025 09:26
Weekly Report: what happened at EXOZ last week (1124-1128)?
Weekly Report · 12/01/2025 09:24
Weekly Report: what happened at EXOZ last week (1117-1121)?
Weekly Report · 11/24/2025 09:26
eXoZymes Inc trading resumes
TipRanks · 11/19/2025 15:40
eXoZymes Inc trading halted, volatility trading pause
TipRanks · 11/19/2025 15:35
Slack Capital Calls eXoZymes a Once-in-a-Lifetime Biotech Opportunity
Reuters · 11/19/2025 14:49
Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology
Reuters · 11/18/2025 21:26
Weekly Report: what happened at EXOZ last week (1110-1114)?
Weekly Report · 11/17/2025 09:26
Exozymes Inc. Reports Significant Losses Amid Financial Challenges
TipRanks · 11/14/2025 04:51
eXoZymes Releases Updated Investor Presentation
TipRanks · 11/13/2025 21:41
Exozymes Inc. posts Q3 net loss of $2.29 million
Reuters · 11/13/2025 21:30
Exozymes Inc. Names Tyler Korman as CSO and Amy Lunzer as Chief of Staff
Reuters · 11/13/2025 21:18
More
Webull provides a variety of real-time EXOZ stock news. You can receive the latest news about eXoZymes Inc through multiple platforms. This information may help you make smarter investment decisions.
About EXOZ
Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The Company's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The Company is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. It can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).